肌层浸润性膀胱癌新辅助剂量密集吉西他滨联合顺铂的2期试验结果
这项2期试验评估了肌层浸润性膀胱癌患者接受三个14天周期剂量密集吉西他滨联合顺铂(DDGC)新辅助化疗后行根治性膀胱切除术的安全性和有效性。结论提示DDGC的pT0率与历史标准GC回顾性数据相似,但血管事件风险需警惕。
要点
- DDGC新辅助化疗的ypT0N0率为32%(95%CI 16-49%),与标准GC历史回顾数据相似。
- 23%患者发生临床显著血管事件,导致研究提前终止,需谨慎使用该方案。
- 94%患者接受膀胱切除术,化疗开始至手术中位时间9.3周。
核心结论
- DDGC的pT0率与标准GC回顾性数据相似,但血管事件导致23%患者手术受阻或延迟,研究提前终止。
研究设计与样本
- 前瞻性2期试验,纳入cT2-4a、N0-1、M0肌层浸润性膀胱癌患者,接受三个14天周期DDGC联合聚乙二醇化非格司亭支持后行根治性膀胱切除术加淋巴结清扫。
主要发现
- 54.8%患者仅发生1-2级治疗相关毒性,但7例(23%)发生临床显著血管事件。
- 分子亚型与生存无相关性。
关键数值与推荐
- 主要终点pT0率:32%(95%CI 16-49%)。
- 降期至<pT2N0率:13%(95%CI 1-25%)。
- 血管事件发生率:23%。
- 膀胱切除术完成率:94%。
- 化疗至手术中位时间:9.3周。
临床怎么用
- DDGC新辅助方案因血管事件风险较高需谨慎使用,尤其在有更安全有效的替代方案(如剂量密集或加速MVAC)前瞻性证据时。
- 需开展嵌入生物标志物相关性的前瞻性研究以准确界定GC新辅助治疗的活性和毒性。
局限性
- 分子亚型与生存无相关性,但样本量可能不足以检测差异。
- 缺乏与标准GC的前瞻性随机对照比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accelerated (also termed dose-dense, DD) chemotherapy regimens such as accelerated methotrexate, vinblastine, doxorubicin, and cisplatin have shown better efficacy and tolerability in the metastatic setting, and shortened the time to surgery in the neoadjuvant setting compared to standard-schedule regimens. We hypothesized that a DD schedule of gemcitabine and cisplatin (GC) would shorten the time to surgery and yield similar pathologic complete response rates (pT0) in patients with muscle-invasive bladder cancer (MIBC) compared with historical controls with standard GC. OBJECTIVE: To determine the safety and efficacy of neoadjuvant DDGC in MIBC. DESIGN SETTING AND PARTICIPANTS: Patients with cT2-4a, N0-1, M0 MIBC were eligible and received three 14-d cycles of DDGC with pegfilgrastim support followed by radical cystectomy with lymph node dissection. The primary end point was the pT0 rate. Molecular subtypes were assigned and correlated with survival. RESULTS AND LIMITATIONS: Thirty-one patients were evaluable for toxicity and response, of whom 58% had baseline clinical stage >T2N0M0; the median age was 69 yr. Ten patients (32%, 95% confidence interval [CI] 16-49%) achieved ypT0N0 status at cystectomy. Another four patients (13%, 95% CI 1-25%) were downstaged to non-muscle-invasive (<pT2N0) disease. Most patients (54.8%) experienced only grade 1-2 treatment-related toxicities. However, seven patients (23%) had clinically significant vascular events, leading to early closure of the study. Thirty patients (94%) underwent cystectomy. The median time from the start of chemotherapy to cystectomy was 9.3 wk. There was no correlation between molecular subtypes and survival. CONCLUSIONS: DDGC yielded a similar pT0 rate to that noted retrospectively with standard GC. Vascular events precluded, delayed, or increased the risk of surgery for 23% of patients, resulting in early closure of the study. Additional prospective studies with embedded biomarker correlatives of GC in the neoadjuvant setting are critical to accurately define both the activity and toxicity of this combination in MIBC. PATIENT SUMMARY: Neoadjuvant chemotherapy before cystectomy is the standard of care for muscle-invasive bladder cancer (MIBC). This prospective phase 2 study tested a dose-dense schedule of gemcitabine and cisplatin in MIBC. The study was closed early because of a higher than expected rate of vascular events. These data suggest that caution is required in using this regimen, particularly when there is better prospective evidence for the safety and efficacy of alternative regimens such as dose-dense or accelerated methotrexate, vinblastine, doxorubicin, and cisplatin.
引用
- Anari F, O'Neill J, Choi W, et al. Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol. 2018. PMID: 30420974. doi:10.1016/j.euo.2018.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。